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ABSTRACT: Specialized pro-resolving lipid mediators are biosynthesized during the resolution phase of acute inﬂammation
from n-3 polyunsaturated fatty acids. Recently, the isolation and identiﬁcation of the four novel mediators denoted 13-series
resolvins, namely, RvT1 (1), RvT2 (2), RvT3 (3) and RvT4 (4), were reported, which showed potent bioactions characteristic
for specialized pro-resolving lipid mediators. Herein, based on results from LC/MS-MS metabololipidomics and the
stereoselective synthesis of 13(R)-hydroxy-7Z,10Z,13R,14E,16Z,19Z docosapentaenoic acid (13R-HDPA, 5), we provide direct
evidence that the four novel mediators 1−4 are all biosynthesized from the pivotal intermediate 5. The UV and LC/MS-MS
results from synthetic 13R-HDPA (5) matched those from endogenously and biosynthetically produced material obtained from
in vivo infectious exudates, endothelial cells, and human recombinant COX-2 enzyme. Stereochemically pure 5 was obtained with
the use of a chiral pool starting material that installed the conﬁguration at the C-13 atom as R. Two stereoselective Z-Wittig
reactions and two Z-selective reductions of internal alkynes aﬀorded the geometrically pure alkene moieties in 5. Incubation of 5
with isolated human neutrophils gave all four RvTs. The results presented herein provide new knowledge on the biosynthetic
pathways and the enzymatic origin of RvTs 1−4.
During the resolution of acute inﬂammation, a novel groupof host-protective chemical mediators biosynthesized
from the n-3 polyunsaturated fatty acids (PUFAs) eicosapen-
taenoic acid (EPA) and docosahexaenoic acid (DHA), termed
specialized pro-resolving mediators (SPMs)1 and their bioactive
peptide-conjugates,2 are resolution mediators and control tissue
regeneration and promote the return to homeostasis.3,4 The
resolvins, protectins, and maresins constitute individual families
of SPMs that are formed via distinct biosynthetic pathways.4
During the resolution of acute inﬂammation, SPMs exhibit a
wide range of potent pro-resolving actions, which include
promoting the clearance of bacteria and apoptotic cells,
counter-regulating the production and actions of pro-
inﬂammatory mediators, and stimulating the resolution of
inﬂammation.5 The PUFA n-3 docosapentaenoic acid (n-3
DPA) is an intermediate in the biosynthesis of DHA from EPA
and is also a precursor to novel bioactive mediators.6−8 The
isolation and structure elucidation of four new host-protective
molecules was recently reported. These compounds were
termed 13-series resolvins (RvTs), namely, RvT1 (1), RvT2
(2), RvT3 (3) and RvT4 (4), given that they share a hydroxy
functionality at carbon 13.8
These four enzymatically oxygenated products are bio-
synthesized during neutrophil-endothelial cocultures and are
present, after sterile inﬂammation as well as infection, in both
human and mouse tissues. These four new natural products are
biosynthesized from n-3 DPA during neutrophil-endothelial
interactions where endothelial cyclooxygenase-2 (COX-2)
converts n-3 docosapentaenoic acid to 13-hydro(peroxy)-
7Z,10Z,13,14E,16Z,19Z docosapentaenoic acid that is then
thought to react rapidly, via COX-2-mediated peroxidase
activity, into 13(R)-hydroxy-7Z,10Z,13R,14E,16Z,19Z docosa-
pentaenoic acid (Scheme 1).8 The RvTs contain conjugated
diene and triene moieties, as well as isolated Z-oleﬁns, in
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addition to the common hydroxy functionality at C-13. The
RvT family of mediators demonstrated potent protective
actions increasing mice survival during Escherichia coli (E.
coli) infections, and regulate human and mouse phagocyte
responses that result in increased bacterial phagocytosis and
regulation of inﬂammasome components.8
The presence of a secondary alcohol functionality at C-13 in
all four RvTs caught our attention as a common and important
chemical feature that most likely is involved early in the
biosynthesis of all four RvTs. LC/MS-MS-based experiments
using lipid mediator metabololipidomics with materials
obtained from human neutrophil-endothelial cell interactions
allowed for the identiﬁcation of a 13-hydroxylated C22-
compound biosynthesized in human endothelial cell assays.
Incubations of n-3 DPA with human recombinant cyclo-
oxygenase-2 (hrCOX-2), together with UV experiments and
chiral-phase LC-MS/MS analyses, provided evidence for the
involvement of the hydroperoxide of a 13(R)-hydroxy-
docosapentaenoic acid intermediate (13R-HpDPA) in the
biosynthesis of the 13 series resolvins.8 Given the potency of
these molecules (pM−nM) and the fact that they are produced
in small amounts (pg−ng) within biological systems, it was not
possible to determine the exact conﬁgurations of the double
bonds or the absolute conﬁgurations of the secondary alcohols
in RvTs 1−4. Based on biosynthetic considerations,4,5,9 we
tentatively assigned the conﬁgurations of the double bonds as
depicted.
As bacterial infections in humans remain a serious health
concern due to the rise in antibiotic resistance toward existing
antibacterial therapeutics, an imminent need for new treatment
strategies exists.10 Of interest toward this aim, the RvTs 1−4
exert anti-inﬂammatory and potent pro-resolving activities by
regulating key innate protective responses during E. coli
infections in mice.8 Due to the interesting and potent biological
activities of the RvTs 1−4, it is of considerable interest to
further investigate their biosynthetic pathways. Herein, we
present direct evidence for the conﬁgurational assignment of
the key biosynthetic intermediate in the RvT pathway, namely,
13R-HDPA (5), by matching material obtained from total
synthesis with that isolated from (a) human endothelial cells,
(b) mouse infectious exudates, and (c) human recombinant
COX-2. We also demonstrate that 13R-HDPA is converted by
human neutrophils to all four RvTs, thereby conﬁrming the role
of 13R-HDPA as a key biosynthetic intermediate in RvT
formation.
■ RESULTS AND DISCUSSION
To establish evidence of the existence of 13R-HDPA (5) as a
pivotal intermediate and its role in the biosynthesis of the novel
13-series resolvins (RvT 1−4), stereochemically pure 5 was
obtained by total synthesis. First, a synthesis of the terminal
alkyne 10 from commercially available 2-pentyn-1-ol (6),
Scheme 2, was needed. The preparation of diyne 8 was
performed as previously reported.11 Unfortunately, attempted
Lindlar reduction of the internal alkyne in 8 gave no conversion
to wanted 9. However, the stereoselective Z-reduction of the
internal alkyne was successfully achieved with P-2 nickel boride
(P-2 Ni),12,13 which provided 9 in 80% yield. Removal of the
TMS-protecting group was achieved using TBAF buﬀered with
acetic acid. Addition of acetic acid was absolutely necessary to
suppress the formation of the E-isomer of 10. The modest
overall yield of 10 by this sequence is attributed to the high
volatility of 10.
Next, vinyl iodide 13 was prepared from commercially
available (R)-α-hydroxy-γ-butyrolactone (11), via known
alcohol 12.14 An alkyne hydrozirconation of 12, followed by
treatment with iodine, furnished the vinyl iodide 13 in fair yield
(Scheme 3).
The Wittig salt 19 was prepared from cycloheptanone (14)
in eight steps. Phosphonium salt 15 was obtained as previously
reported7 in a sequence involving a Baeyer−Villager oxidation
of 14, subsequent methanolysis of the resulting lactone,
Scheme 1. Chemical Structure of 13R-HDPA (5) and
Outline of Its Proposed Biosynthesis from n-3 DPA
Scheme 2. Synthesis of (Z)-Hept-4-en-1-yne (10)
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conversion of the formed primary alcohol to its iodide that was
reacted with triphenylphospine to give 15. A Wittig reaction of
15 with TBS-protected 3-hydroxypropanal (16) and subse-
quent removal of the silyl group15 aﬀorded the alcohol 17. This
was then converted into the corresponding iodide 18 via an
Appel reaction, followed by treatment with triphenylphospine
in reﬂuxing acetonitrile that aﬀorded the desired Wittig salt 19
in 81% yield over the two steps (Scheme 4).
Then terminal alkyne 10 and vinyl iodide 13 were assembled
in a Sonogashira cross-coupling reaction, which produced the
conjugated enyne 20 in 86% yield. Oxidation of the alcohol in
20 gave aldehyde 21, which was immediately reacted in a Z-
selective Wittig reaction with the ylide of Wittig salt 19; the
latter was generated at −78 °C after treatment with NaHMDS.
This aﬀorded the ester 22 in 77% yield. Finally, after removal of
the silyl group with in situ-generated HCl from AcCl in MeOH,
the internal alkyne in 23 was stereoselectively reduced using the
Boland protocol,16 furnishing the conjugated E,Z-diene 24 in
67% yield (Scheme 5). The chemical purity of ester 24 was
>98%. Saponiﬁcation with LiOH17 aﬀorded chemically (>98%)
and stereochemically pure 13R-HDPA (5) (>99% ee)
according to LC-MS/MS analyses using a chiral-phase column
(Figure 1).
We next tested whether synthetic 5 matched authentic 13R-
HDPA (5). We ﬁrst isolated material from human umbilical
endothelial cells8 that in RP-HPLC-MS-MS metabololipido-
mics18 gave a sharp peak with retention time (RT) of 17.5 min
(Figure 1A). 13-HDPA from infectious exudates and from
hrCOX-2 also eluted with RT 17.5 min (Figure 1B,C). The
same retention time was observed (RT = 17.5 min) for
synthetic 13R-HDPA (5), Figure 1D. Moreover, coinjection of
biological 13-HPDA with synthetic material of 5 gave a single
sharp peak with RT 17.5 min (Figure 1E).
Then we sought evidence for the absolute conﬁguration at C-
13 and that synthetic material of 5 eluted with biological 13R-
HDPA in a chiral environment. In all biological systems tested,
13R-HDPA was the main product giving a sharp peak at RT 5.1
min in a chiral-phase chromatography-tandem mass spectrom-
etry system (Figures 2A−C). Synthetic 13R-HDPA (5) also
gave RT 5.1 min (Figure 2D), and when this material was
coinjected with biological material, a sharp peak only at RT 5.1
min was observed (Figure 2E). Of note, in the endothelial cell
and recombinant enzyme incubations, we also identiﬁed the S-
isomer of 13-HDPA that was found to be the minor product in
both incubations forming ∼10% of the overall 13-HDPA levels
in the HUVEC incubations (Figure 2A) and <5% in the
recombinant enzyme incubations (Figure 2C). This is in
accordance with published ﬁndings that COX-2 stereo-
selectively converts n-3 DPA to the R-conﬁgured stereoisomer
with a small proportion of the substrate being converted to the
S-stereoisomer.8 This is also observed for other enzymes that
lipoxygenate their substrate.19 Altogether, these eﬀorts
established that the synthetic material of 5 eluted together
with biologically produced 13-HDPA and that the absolute
conﬁguration at C-13 is R for biogenic 13-HDPA (5).
To obtain further evidence for matching physical properties
of authentic and synthetic material of 5, MS-MS spectra for
13R-HDPA from HUVEC incubations, infectious exudates and
synthetic material of 5 were recorded, that gave essentially
identical MS-MS spectra including fragments at m/z 327, 301,
283, 223, 205, and 195 (Figure 3A−C).
Scheme 3. Synthesis of Vinyl Iodide 13
Scheme 4. Synthesis of Wittig Salt 19
Scheme 5. Synthesis of 13R-HDPA (5)
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Figure 1. 13-HDPA MRM chromatograms from (A) endothelial cells,
(B) infectious exudates, (C) hrCOX-2, and (D) synthetic material of
5. (E) Coinjection of endothelial and synthetic 5.
Figure 2. 13-HDPA chiral LC-MS-MS derived from (A) endothelial
cells, (B) infectious exudates, (C) hrCOX-2, and (D) synthetic
material. (E) Coinjection of endothelial and synthetic 13R-HDPA.
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Assessment of the UV chromophore of biogenic 13R-HDPA
from hrCOX-2 and that of the synthetic material of 5, both
gave λmax
MeOH of 237 nm (Figure 4A,B), adding additional
conﬁdence in our structural assignment.
We next tested whether the synthetic material 5 was a
substrate for the conversion to any of the four RvTs by human
neutrophils. Incubation of synthetic 13R-HDPA (5) with
human neutrophils gave RvT1 (1), RvT2 (2), RvT3 (3), and
RvT4 (4), as determined using both retention time (Figure 5A)
and MS-MS spectra (Figure 5B). Of note in incubations with
neutrophils without 13R-HDPA (5), levels of RvT1 (1), RvT2
(2), RvT3 (3), and RvT4 (4), were >75% lower than those
found in incubations with the synthetic material. These results
are in accordance with published ﬁndings8 and indicate that
while PMN may utilize endogenous 13R-HDPA, which may be
esteriﬁed and released upon cellular activation as observed for
other SPM biosynthetic intermediates,20 these cells rely on
other cell types to donate this key biosynthetic intermediate for
RvT biosynthesis. Together these results establish the exact
structural assignment of 13R-HDPA as 13(R)-hydroxy-
7Z,10Z,13R,14E,16Z,19Z docosapentaenoic acid (5), as well
as its key role in the RvT biosynthetic pathway.
■ CONCLUSIONS
The biosynthesis of SPMs in human physiological systems
aﬀords the E- and D-series resolvins with either a E,E,Z,E-
tetraene or a E,E,Z-triene moiety.2,4 On the other hand, the
13R-series-resolvins display diene and triene moieties, isolated
Z-oleﬁns, and a hydroxy functionality at C-13. These features
distinguish the 13R-series-resolvins from the established
families of SPMs (i.e., the resolvins, protectins, and maresins),
as well as other oxygenated natural products of nonhuman
origin.21 Herein, we have demonstrated that the COX-2
enzyme is involved in the ﬁrst step in the biosynthetic pathways
of the 13R-series-resolvins. Most likely, as for the other SPM
families,5 the ﬁrst step involves the formation of a hydro-
peroxide intermediate that undergoes distinct enzymatic
multistep sequences to the individual natural products 1−4.
Because all families of SPMs,22 as well as other oxygenated
PUFA-derivatives,21,23 exhibit potent and interesting pharma-
cological actions, these natural products are of interest as lead
compounds toward the clinical development of diﬀerent
treatments for human diseases, via a novel mechanism as
resolution agonists. Such eﬀorts will be more expedient with
knowledge of the complete structural assignment and
biosynthetic pathways of SPMs such as the 13R-series resolvins.
■ EXPERIMENTAL SECTION
General Experimental Procedures. Optical rotations were
measured using a 0.7 mL cell with a 1.0 dm path length on an
Anton Paar MCP 100 polarimeter. The UV−vis spectra from 190 to
900 nm were recorded on a Shimadzu UV-1800 spectrophotometer
using quartz cuvettes. NMR spectra were recorded on a Bruker
AVII400 spectrometer at 400 MHz or a Bruker AVII600 spectrometer
at 600 MHz for 1H NMR, and at 100 or 150 MHz for 13C NMR.
Spectra are referenced relative to the central residual protium solvent
resonance in 1H NMR (CDCl3 δH = 7.27, and MeOH-d4 δH = 3.31)
and the central carbon solvent resonance in 13C NMR (CDCl3 δC =
77.00 ppm, and MeOH-d4 = δC = 49.00). High-resolution mass spectra
were recorded on a Waters Prospec Q spectrometer using ES as the
method of ionization. Thin-layer chromatography was performed on
silica gel 60 F254 aluminum-backed plates fabricated by Merck. Flash
column chromatography was performed on silica gel 60 (40−63 μm)
produced by Merck. HPLC analyses for chemical purities were
performed on an Agilent Technologies 1200 Series instrument with
diode array detector set at 254 nm and equipped with a C18 stationary
phase (Eclipse XDB-C18 5 μm 4.6 × 150 mm), applying the
conditions stated. GLC-analyses were performed on an Agilent
Technologies 7820A GC instrument with split injection, FID detector
and equipped with an Agilent J&W HP-5 GC column (30 m × 0.32
mm, 0.25 μm) applying the conditions stated. Unless stated otherwise,
all commercially available reagents and solvents were used in the form
they were supplied without any further puriﬁcation. All reactions were
performed under an argon atmosphere, unless otherwise stated. The
stated yields are based on isolated material. Liquid chromatography
(LC)-grade solvents were purchased from Fisher Scientiﬁc. The
Eclipse Plus C18 column (100 × 4.6 mm × 1.8 μm) was obtained
from Agilent and C18 SPE columns were from Waters. Commercially
available lipid mediators were obtained from Cayman Chemical.
Figure 3. MS-MS spectra employed in the identiﬁcation of 13-HDPA
from (A) endothelial cells, (B) infectious exudates, and (C) synthetic
material. n = 3 endothelial cell donors, n = 3 mouse exudates, and n =
3 for synthetic material.
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(Z)-Hept-4-en-1-yn-1-yltrimethylsilane (9). A suspension of
sodium borohydride (32.9 mg, 0.87 mmol) in EtOH (1.3 mL) was
added dropwise to a ﬂask containing nickel acetate tetrahydrate (217
mg, 0.87 mmol, 14 mol%) in EtOH (13.0 mL) at 0 °C under stirring.
The reaction mixture turned black. After stirring for 15 min at room
temperature, ethylenediamine (116 μL, 105 mg, 1.74 mmol) was
added, and the stirring was continued for 10 min. The ﬂask was
evacuated and reﬁlled with hydrogen gas before the skipped diyne 811
was added (1.00 g, 6.09 mmol, 1.00 equiv). The reaction mixture was
stirred at room temperature under hydrogen atmosphere until
completion (∼4 h), then ﬁltered through a short plug of silica gel
that was washed with pentane (10 mL). The ﬁltrate was transferred to
a separatory funnel and washed with H2O (3 × 5.0 mL). The organic
layer was dried (MgSO4), and the solvent was removed in vacuo.
Figure 4. UV spectra for (A) hrCOX-2 13-HDPA and (B) synthetic 13R-HDPA (5).
Figure 5. Human neutrophils convert 13R-HDPA (5) to RvT1−4 (1−4). Human neutrophils were isolated from peripheral blood of healthy donors
and incubated (2 × 107 cells/mL) with or without 13R-HDPA (5) (45 min, 37 °C, 2 μM A23187, PBS, pH = 7.45). Incubations were quenched with
two volumes of ice cold MeOH and products extracted and proﬁled using lipid mediator metabololipidomics. (A) MRM chromatograms for each of
the RvT1−4 with relative abundances to their levels in each of the incubations. (B) MS-MS spectra employed in the identiﬁcation of RvT1 (1),
RvT2 (2), RvT3 (3) and RvT4 (4). Results are representative of n = 3 healthy volunteers.
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Puriﬁcation by ﬂash chromatography on silica gel (pentane) aﬀorded
the desired product 9 as a colorless oil. Yield: 810 mg (80%); 1H NMR
(400 MHz, CDCl3) δH 5.51−5.42 (m, 1H), 5.42−5.35 (m, 1H), 2.98
(m, 2H), 2.06 (p, J = 7.5 Hz, 2H), 0.98 (t, J = 7.5 Hz, 3H), 0.15 (s,
9H). 13C NMR (101 MHz, CDCl3) δC 133.7, 123.4, 105.7, 84.2, 20.7,
18.4, 14.1, 0.3. TLC (hexane, KMnO4 stain) Rf = 0.12. The
spectroscopic data were in agreement with those previously reported
for this compound.24
(Z)-Hept-4-en-1-yne (10). (Z)-Hept-4-en-1-yn-1-yltrimethylsilane
(9) (700 mg, 4.21 mmol, 1.00 equiv) was added to a solution of TBAF
(1.0 M in THF, 6.74 mL, 6.74 mmol, 1.60 equiv) and acetic acid (0.40
mL, 6.95 mmol). The reaction was stirred at room temperature for 16
h and quenched with H2O (6.0 mL). Pentane (40 mL) was added, and
the organic layer was washed with saturated aq NaHCO3 (7.0 mL),
water (10 × 7.0 mL) to remove the remaining THF, and then dried
(MgSO4). Pentane was removed by distillation. After distillation, the
product still contained traces of solvents, but that was accounted for in
the next step. Yield: 189 mg (47%); 1H NMR (400 MHz, CDCl3) δH
5.53−5.45 (m, 1H), 5.44−5.36 (m, 1H), 2.94 (m, 2H), 2.13−2.00 (m,
2H), 1.97 (t, J = 2.7 Hz, 1H), 0.99 (t, J = 7.5 Hz, 3H); 13C NMR (101
MHz, CDCl3) δC 134.0, 123.1, 83.2, 68.1, 20.6, 16.9, 14.0. The
spectroscopic data were in agreement with those previously reported
for this compound.25
(R,E)-3-((tert-Butyldimethylsilyl)oxy)-5-iodopent-4-en-1-ol (13).
Compound 12 was prepared as previously reported.14 The Schwartz’s
reagent was prepared in situ following the procedure by Huang and
Negishi.26 Cp2ZrCl2 (1.24 g, 4.23 mmol, 2.10 equiv) in THF (5.00
mL) was cooled to 0 °C and stirred under argon. A solution of
DIBAL-H (1.0 M in THF, 4.23 mL, 4.23 mmol) was added dropwise.
The resultant suspension was stirred for 30 min at 0 °C and protected
from light with aluminum foil, before the terminal alkyne 12 (431 mg,
2.02 mmol, 1.00 equiv) in THF (1.00 mL) was added. The cooling
bath was removed, and the reaction mixture stirred at room
temperature until a homogeneous solution was observed (ca. 1 h)
and then cooled to −78 °C. A solution of I2 (665 mg, 5.24 mmol, 1.24
equiv) in THF/CH2Cl2 (3.00 mL, 1:1) was added. The reaction
mixture was stirred 45 min before it was ﬁltered through a plug of silica
gel that was successively washed with 20% EtOAc in heptane. The
solvent was removed under reduced pressure, and the crude product
was puriﬁed by column chromatography on silica gel (heptane/EtOAc
8:2) to aﬀord the vinyl iodine 13 as a pale yellow oil. Yield: 385 mg
(56%); [α]D
20 + 58 (c = 0.29, MeOH); 1H NMR (400 MHz, CDCl3)
δH 6.56 (dd, J = 14.4, 6.0 Hz, 1H), 6.29 (dd, J = 14.4, 1.2 Hz, 1H),
4.37 (m, 1H), 3.79 (ddd, J = 10.9, 7.9, 4.3 Hz, 1H), 3.70 (m, 1H), 2.02
(s, 1H), 1.81 (m, 1H), 1.72 (m, 1H), 0.90 (s, 9H), 0.09 (s, 3H), 0.06
(s, 3H); 13C NMR (101 MHz, CDCl3) δC 148.4, 76.5, 74.3, 59.7, 39.1,
25.9 (3C), 18.3, −4.4, −4.9;. HRESITOFMS: m/z 365.0403 [M +
Na]+ (calcd for C11H23IO2SiNa, 365.0410); TLC (hexane/EtOAc 7:3,
KMnO4 stain) Rf = 0.37.
Methyl (Z)-10-hydroxydec-7-enoate (17). The ester 17 was
prepared according to a literature procedure.2c The known Wittig
salt 157 (1.70 g, 3.19 mmol, 1.00 equiv) was dissolved in THF (42.0
mL) and HMPA (4.20 mL) and cooled to −78 °C. NaHMDS (0.60 M
in toluene, 5.30 mL, 3.18 mmol, 1.00 equiv) was added dropwise, and
the reaction mixture was stirred for 30−45 min. Aldehyde 6 (631 mg,
3.35 mmol, 1.05 equiv) in THF (4.20 mL) was then added dropwise,
and stirring was continued for 1.5 h at −78 °C. The ﬂask was allowed
to slowly warm up to 0 °C, and the reaction was quenched with
phosphate buﬀer (21.1 mL, pH = 7.2). The aq phase was extracted
with Et2O (2 × 20.0 mL), and the combined organic layers were dried
(Na2SO4) and concentrated in vacuo. The crude material was passed
through a short plug of silica that was washed with 5% EtOAc in
heptane (Rf = 0.26). The crude product (868 mg, 2.76 mmol, 1.00
equiv) was dissolved in CH2Cl2/MeOH (1:2, 34.0 mL) and cooled to
0 °C. Camphor-10-sulfonic acid (642 mg, 2.76 mmol, 1.00 equiv) was
added in one portion, and the reaction mixture was stirred for 30 min
at 0 °C before it was allowed to slowly warm up to room temperature
and stirred for 1 h. The reaction was quenched with saturated aq
NaHCO3 (33.3 mL), extracted with CH2Cl2 (2 × 15.0 mL), dried
(Na2SO4), and concentrated in vacuo. The crude product was puriﬁed
by column chromatography on silica gel (heptane/EtOAc 7:3) to
aﬀord hydroxyl methyl ester 17 as a clear oil. The chemical purity
(>99%) was determined by GLC analysis: Initial temperature 100 °C,
rate: 5 °C/min, ﬁnal temperature 200 °C, tr (minor) = 8.90 min, tr
(major) = 9.22 min. Yield: 483 mg (76%); 1H NMR (400 MHz,
MeOH-d4) δH 7.08−6.90 (m, 2H), 5.21 (s, 3H), 5.09 (t, J = 7.0 Hz,
2H), 3.92−3.77 (m, 4H), 3.64 (q, J = 6.7 Hz, 2H), 3.18 (q, J = 7.3 Hz,
2H), 2.93 (m, 4H). 13C NMR (101 MHz, MeOH-d4) δC 176.0, 132.7,
126.9, 62.8, 51.9, 34.8, 31.8, 30.4, 29.8, 28.1, 25.9. HRMS (TOF ES+):
m/z 223.1305 [M + Na]+ (calcd for C11H20O3Na, 223.1310). TLC
(Heptane/EtOAc 7:3, KMnO4 stain): Rf = 0.23.
Methyl (Z)-10-(iodotriphenyl-λ5-phosphanyl)dec-7-enoate (19).
Iodide 18 was prepared from hydroxy ester 17 (483 mg, 2.42 mmol,
1.00 equiv) according to a procedure reported by Mioskowski and co-
workers27 and used directly in the next reaction. Iodide 18 (638 g, 2.06
mmol, 1.00 equiv) was dissolved in dry MeCN (20.0 mL).
Triphenylphosphine (1.08 g, 4.12 mmol, 2.00 equiv) was added, and
the reaction mixture was heated to reﬂux for 12 h. The reaction
mixture was concentrated in vacuo. The crude product was puriﬁed by
column chromatography on silica gel (CH2Cl2/MeOH 95:5) to aﬀord
the Wittig salt 19 as a clear oil. Yield: 1.12 g (81%); 1H NMR (400
MHz, MeOH-d4) δ 8.00−7.64 (m, 15H), 5.56−5.42 (m, 2H), 3.63 (s,
3H), 3.57−3.45 (m, 2H), 2.49−2.38 (m, 2H), 2.28 (t, J = 7.3 Hz, 2H),
1.90 (q, J = 6.8 Hz, 2H), 1.52 (p, J = 7.4 Hz, 2H), 1.36−1.19 (m, 4H).
13C NMR (101 MHz, MeOH-d4) δC 175.8, 136.3 (d, 4′JCP = 3.0 Hz,
3C), 134.9 (d, 3′JCP = 10.0 Hz, 6C), 133.5, 131.6 (d, 2′JCP = 12.6 Hz,
6C), 127.4 (d, 3′JCP = 16.1 Hz), 119.8 (d, 1′JCP = 86.2 Hz, 3C), 52.0,
34.6, 29.9, 29.6, 27.9, 25. 7, 23.0 (d, 1′JCP = 49.2 Hz), 21.3 (d, 2′JCP =
3.3 Hz). HRESITOFMS: m/z 445.2287 [M]+ (calcd for C29H34O2P,
445.2296); TLC (CH2Cl2/MeOH 95:5) Rf = 0.47.
(R,4E,9Z)-3-((tert-Butyldimethylsilyl)oxy)dodeca-4,9-diene-6-yn-
1-ol (20). To a solution of vinyl iodide 13 (385 mg, 1.13 mmol, 1.00
equiv) in Et2NH (2.50 mL) and benzene (2.20 mL) was added
Pd(PPh3)4 (39.2 mg, 33.9 μmol, 3.00 mol%). The reaction mixture
was stirred for 45 min in the dark before CuI (11.2 mg, 58.8 μmol,
5.00 mol%) in a minimum amount of Et2NH was added followed by
dropwise addition of alkyne 10 (213 mg) in Et2NH (2.20 mL). After
stirring for 20 h at room temperature, the reaction was quenched with
a saturated aq solution of NH4Cl (23 mL). The aq phase was extracted
with Et2O (3 × 3.0 mL) before the combined organic layers were dried
(Na2SO4) and concentrated in vacuo. The crude product was puriﬁed
by column chromatography on silica gel (heptane/EtOAc 8:2) to
aﬀord compound 20 as an orange oil. Yield: 299 mg (86%); [α]D
20 + 32
(c 0.40, MeOH); 1H NMR (400 MHz, CDCl3) δH 6.04 (dd, J = 15.8,
5.7 Hz, 1H), 5.65 (dq, J = 15.8, 2.1 Hz, 1H), 5.51−5.43 (m, 1H),
5.43−5.34 (m, 1H), 4.43 (q, J = 4.9 Hz, 1H), 3.78 (m, 1H), 3.68 (m,
1H), 3.05 (d, J = 6.6 Hz, 2H), 2.27 (s, 1H), 2.12−1.99 (m, 2H), 1.83
(m, 1H), 1.69 (m, 1H), 0.98 (t, J = 7.5 Hz, 3H), 0.90 (s, 9H), 0.08 (s,
3H), 0.05 (s, 3H); 13C NMR (101 MHz, CDCl3) δC 144.1, 133.7,
123.4, 110.1, 89.4, 78.2, 72.0, 59.9, 39.4, 25.9, 20.6, 18.2, 17.9, 14.1,
−4.3, −4.9; HRESITOFMS: m/z 331.2063 [M + Na]+ (calcd for
C18H32O2SiNa, 331.2064); TLC (hexane/EtOAc 7:3, KMnO4 stain)
Rf = 0.37.
(R,4E,9Z)-3-((tert-Butyldimethylsilyl)oxy)dodeca-4,9-dien-6ynal
(21). Alcohol 20 (240 mg, 77.9 μmol, 1.00 equiv) was dissolved in
CH2Cl2 (23.0 mL) before NaHCO3 (375 mg, 4.46 mmol, 5.70 equiv)
and Dess−Martin periodinane (406 mg, 95.7 μmol, 1.23 equiv) were
added. The reaction mixture was stirred at room temperature for 3 h
before saturated aq Na2S2O3 (5.0 mL) was added to quench the
reaction. The aq phase was extracted with CH2Cl2 (2 × 7.0 mL), and
the combined organic layers were dried and concentrated in vacuo.
The crude product was puriﬁed by column chromatography on silica
gel (heptane/EtOAc 8:2) to aﬀord aldehyde 21 as a pale yellow oil.
Yield: 219 mg (91%); [α]D
20 + 19 (c 0.41, MeOH); 1H NMR (400
MHz, CDCl3) δH 9.75 (t, J = 2.3 Hz, 1H), 6.07 (dd, J = 15.8, 5.6 Hz,
1H), 5.72 (dq, J = 15.8, 2.1 Hz, 1H), 5.55−5.34 (m, 2H), 4.68 (m,
1H), 3.11−3.02 (m, 2H), 2.61 (ddd, J = 16.0, 6.7, 2.5 Hz, 1H), 2.52
(ddd, J = 16.0, 5.1, 2.1 Hz, 1H), 2.07 (p, J = 7.3 Hz, 2H), 0.98 (t, J =
7.5 Hz, 3H), 0.87 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H). 13C NMR (101
MHz, CDCl3) δC 201.1, 143.1, 133.8, 123.3, 110.7, 90.1, 77.9, 68.6,
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51.3, 25.9, 20.7, 18.2, 17.9, 14.1, −4.3, −4.9. HRESITOFMS: m/z
329.1907 [M + Na]+ (calcd for C18H30O2SiNa, 329.1913); TLC
(hexane/EtOAc 85:15, KMnO4 stain) Rf = 0.38.
Methyl-(R,7Z,10Z,14E,19Z)-13-((tert-butyldimethylsilyl)oxy)-
docosa-7,10,14,19-tetraen-16-ynoate (22). Wittig salt 19 (374 mg,
65.4 μmol, 1.00 equiv) was dissolved in THF (8.80 mL) and HMPA
(0.88 mL), cooled to −78 °C and added NaHMDS (0.6 M in toluene,
1.09 mL, 65.4 μmol, 1.00 equiv). The reaction mixture was stirred for
45 min before aldehyde 21 (200 mg, 65.5 μmol, 1.00 equiv) in THF
(0.88 mL) was added dropwise. The reaction was stirred for 1 h at
−78 °C and then the reaction mixture was allowed to slowly warm to
0 °C. Phosphate buﬀer (4.7 mL, pH = 7.2) was added to quench the
reaction and the aq. phase was extracted with Et2O (2 × 4.0 mL). The
combined organic layers were dried (Na2SO4) and concentrated in
vacuo. The crude product was puriﬁed by column chromatography on
silica gel (heptane/EtOAc 95:5, KMnO4 stain) to aﬀord compound 22
as a pale yellow oil. Yield: 239 mg (77%); [α]D
20 + 2.1 (c 0.39, CHCl3);
1H NMR (400 MHz, MeOH-d4) δH 5.98 (dd, J = 15.8, 5.8 Hz, 1H),
5.62 (dq, J = 15.8, 2.0 Hz, 1H), 5.51−5.29 (m, 6H), 4.22 (q, J = 5.6
Hz, 1H), 3.65 (s, 3H), 3.05 (d, J = 6.7 Hz, 2H), 2.78 (q, J = 5.9 Hz,
2H), 2.32 (t, J = 7.4 Hz, 2H), 2.27 (q, J = 6.9 Hz, 2H), 2.08 (q, J = 7.0
Hz, 4H), 1.62 (p, J = 7.5 Hz, 2H), 1.45−1.28 (m, 4H), 0.99 (t, J = 7.5
Hz, 3H), 0.91 (s, 9H), 0.07 (s, 3H), 0.05 (s, 3H) ; 13C NMR (101
MHz, MeOH-d4) δC 175.9, 145.6, 134.2, 131.3, 130.9, 129.0, 126.2,
124.8, 110.8, 89.7, 79.1, 74.0, 52.0, 37.1, 34.8, 30.4, 29.8, 28.1, 26.8,
26.40 (3C), 25.9, 21.4, 19.1, 18.2, 14.4, −4.3, −4.5; HRESITOFMS:
m/z 495.3265 [M + Na]+ (calcd for C29H48O3SiNa, 495.3270); TLC
(hexane/EtOAc 85:15, KMnO4 stain) Rf = 0.47.
Methyl-(R,7Z,10Z,14E,19Z)-13-hydroxydocosa-7,10,14,19-tet-
raen-16-ynoate (23). The TBS-protected intermediate 22 (64.1 mg,
0.136 mmol, 1.00 equiv) was twice azeotroped with 2-Me-THF and
then stirred under argon at 0 °C before a solution of AcCl in dry
MeOH (1.00 mL, 20.4 μmol, 15.0 mol%) was added. The solution of
AcCl in MeOH was prepared just prior to use by adding AcCl (3.0
μL) to dry MeOH (2.0 mL) under argon. The reaction mixture was
stirred for 7 h at 0 °C. Then CH2Cl2 (2.7 mL) was added, and the
reaction was neutralized with a 10% aq solution of NaHCO3 (140 μL)
and washed with H2O (1.4 mL). The combined organic layers were
dried (Na2SO4), and the solvent was removed in vacuo, before the
crude product was puriﬁed by column chromatography on silica gel
(heptane/EtOAc 85:15) to aﬀord the alcohol 23 as a clear oil. Yield:
44.7 mg (92%); [α]D
20 = −9.0 (c = 0.27, MeOH); UV(MeOH) λmax
229, (log ε 3.97); 1H NMR (400 MHz, MeOH-d4) δH 6.01 (dd, J =
15.9, 6.1 Hz, 1H), 5.66 (dq, J = 15.9, 2.2 Hz, 2H), 5.52−5.32 (m, 6H),
4.11 (dq, J= 6.4, 1.0 Hz, 1H), 3.67 (s, 3H), 3.06 (d, J = 6.8 Hz, 2H),
2.81 (m, 2H), 2.38−2.27 (m, 4H), 2.15−2.05 (m, 4H), 1.64 (p, J = 7.4
Hz, 2H), 1.47−1.29 (m, 4H), 1.00 (t, J = 7.5 Hz, 3H). 13C NMR (101
MHz, MeOH-d4) δC 176.0, 145.2, 134.2, 131.4, 131.0, 128.9, 126.0,
124.8, 111.2, 89.6, 79.1, 72.7, 52.0, 36.1, 34.8, 30.4, 29.8, 28.0, 26.8,
25.9, 21.4, 18.2, 14.3; HRESITOFMS: m/z 381.2400 [M+Na]+ (calcd
for C23H34O3Na, 381.2406); TLC (hexane/EtOAc 80:20, KMnO4
stain) Rf = 0.36. The chemical purity (>98%) was determined by
HPLC analysis (Eclipse XDB-C18, MeOH/H2O 85:15, 1.0 mL/min):
tr (major) = 12.94 min and tr (minor) = 15.74 min.
Methyl (R,7Z,10Z,14E,16Z,19Z)-13-hydroxydocosa-7,10,14,16,19-
pentaenoate (24). The activated Zn was prepared according to the
literature.16 A suspension of Zn dust (2.04 g) in distilled H2O (12.3
mL) was stirred under argon for 15 min. Cu(OAc)2·H2O (204 mg,
1.02 mmol) was added, the ﬂask was sealed immediately, and the
mixture stirred vigorously for 15 min. Then AgNO3 (204 mg, 1.2
mmol) was added (exothermic reaction), and the reaction mixture was
stirred for an additional 30 min. The activated Zn was ﬁltered under
argon atmosphere and washed successively with H2O, MeOH,
acetone, and Et2O to give a wet material (the activated Zn was not
dried completely). Alkyne 23 (30 mg, 83.7 μmol) was dissolved in
MeOH/H2O (2:1) (6.00 mL), and then the wet activated Zn was
added quickly under a blanket of argon. The reaction was stirred for 10
h in the dark. After completion, the mixture was ﬁltered through Celite
with Et2O, and the aq phase was extracted with EtOAc (3 × 3.0 mL).
The organic layers were dried (Na2SO4) and the solvent removed in
vacuo, before the crude product was puriﬁed by column chromatog-
raphy on silica gel (heptane/EtOAc 90:10) to aﬀord the methyl ester
24 as a clear oil. Yield 20.2 mg (67%): [α]D
20 − 0.5 (c = 0.74, MeOH);
UV(MeOH) λmax 237, (log ε = 4.41);
1H NMR (400 MHz, MeOH-
d4) δH 6.55 (ddt, J = 15.1, 11.0, 1.1 Hz, 1H), 5.97 (t, J = 10.9 Hz, 1H),
5.68 (dd, J = 15.2, 6.5 Hz, 1H), 5.50−5.26 (m, 7H), 4.15 (q, J = 6.5
Hz, 1H), 3.65 (s, 3H), 2.94 (t, J = 7.2 Hz, 2H), 2.80 (t, J = 5.5 Hz,
2H), 2.43−2.21 (m, 4H), 2.18−2.02 (m, 4H), 1.61 (p, J = 7.4 Hz,
2H), 1.46−1.26 (m, 4H), 0.98 (t, J = 7.5 Hz, 3H); 13C NMR (101
MHz, MeOH-d4) δC 176.0, 137.2, 133.1, 131.2, 131.0, 130.9, 129.2,
129.0, 127.8, 126.4, 126.4, 73.1, 52.0, 36.4, 34.8, 30.4, 29.8, 28.0, 26.9,
26.8, 25.9, 21.5, 14.6; HRESITOFMS: m/z 383.2555 [M + Na]+
(calcd for C23H36O3Na, 383.2562); TLC (hexane/EtOAc 75:25,
KMnO4 stain) Rf = 0.33. The chemical purity (>98%) was determined
by HPLC analysis (Eclipse XDB-C18, MeOH/H2O 85:15, 1.0 mL/
min): tr (minor) = 13.72 and 17.53 min, and tr (major) = 16.53 min.
(R,7Z,10Z,14E,16Z,19Z)-13-Hydroxydocosa-7,10,14,16,19-pen-
taenoic Acid, 13R-HDPA (5). Methyl ester 24 (12.0 mg, 33.3 μmol,
1.00 equiv) was dissolved in THF/MeOH/H2O (2:2:1, 3.90 mL) and
cooled to 0 °C. LiOH (24 mg, mmol, 30.0 equiv) was added in one
portion. The reaction mixture was stirred for 3 h at 0 °C before it was
allowed to warm up to room temperature and stirred until completion,
as monitored by TLC (∼2 h). Saturated aq NaH2PO4 (6.0 mL) was
added. The aq phase was extracted (2 × 3.0 mL), dried (Na2SO4), and
the solvent was removed in vacuo. The crude product was puriﬁed by
column chromatography on silica gel (heptane/EtOAc 50:50, KMnO4
stain) to aﬀord the hydroxy acid 5 as colorless oil. Yield: 10.0 mg
(87%); [α]D
25 - 0.64 (c = 0.47, MeOH); UV(MeOH) λmax 236, (log ε =
4.39); 1H NMR (400 MHz, MeOH-d4) δH 6.55 (ddt, J = 15.2, 11.1,
1.2 Hz, 1H), 5.97 (t, J = 10.9 Hz, 1H), 5.68 (dd, J = 15.2, 6.5 Hz, 1H),
5.49−5.26 (m, 7H), 4.15 (q, J = 6.5 Hz, 1H), 2.94 (t, J = 7.2 Hz, 2H),
2.80 (t, J = 5.8 Hz, 2H), 2.40−2.22 (m, 4H), 2.09 (q, J = 7.6, 6.9 Hz,
4H), 1.61 (p, J = 7.4 Hz, 2H), 1.38 (m, 4H), 0.98 (t, J = 7.5 Hz, 3H);
13C NMR (101 MHz, MeOH-d4) δC 177.7, 137.1, 133.1, 131.2, 131.1,
130.9, 129.2, 129.0, 127.8, 126.4, 126.4, 73.1, 36.4, 35.0, 30.4, 29.9,
28.1, 26.9, 26.8, 26.0, 21.5, 14.6; HRESITOFMS: m/z 369.2400 [M +
Na]+ (calcd for C22H34O3Na, 369.2406); TLC (hexane/EtOAc 50:50,
KMnO4 stain) Rf = 0.27.
Biogenic 13R-HDPA. Human umbilical vein endothelial cells
(HUVEC; 8.5 × 105 cells/9.6 cm2) were incubated with IL-1β (10
ng/mL) and TNF-α (10 ng/mL; 16 h, 37 °C, 5% CO2). Incubations
were quenched using 2 volumes of MeOH containing deuterium
labeled d8-5S-HETE.
8
In separate experiments n-3 DPA (Cayman Chemical Company)
was incubated with human recombinant COX-2 (Cayman Chemicals;
in 0.1 M Tris-HCl, pH 8.0, 20 μM porcine hematin, 0.67 mM phenol)
for 30 min at room temperature. Incubations were stopped with two
volumes of MeOH and products extracted using diethyl ether.8 13-
HDPA was isolated using RP-HPLC (1260 Series; Agilent
Technologies) and an Agilent C18 Poroshell column (3.5 μm × 4.6
mm × 150 mm) with a mobile phase consisting of MeOH/H2O
(60:40, vol/vol) at 0.5 mL/min that was ramped up to 98:2 (v/v) for
20 min.
Infectious exudates were collected from mice (6−8 week old, male,
FvB, Charles River, UK) 12h after administration of E. coli (105
CFU).28 Exudates were collected in 4 mL of PBS (containing calcium
and magnesium) and placed in 2 volumes of ice-cold MeOH
containing d8-5S-HETE and commercially available lipid mediators.
In these experiments, male FvB mice (6−8 weeks of age) were used.
These animals were maintained on a standard chow pellet diet and had
access to water ad libitum, with a 12-h light−dark cycle. All animal
experiments were approved and performed under the guidelines of the
Ethical Committee for the Use of Animals, Barts and The London
School of Medicine, and in accordance with the U.K. Home Oﬃce
regulations (Guidance on the Operation of Animals, Scientiﬁc
Procedures Act, 1986).
RvT Biosynthesis. Human peripheral blood was collected according
to a protocol approved by Barts and the London Research Ethics
Committee, London, United Kingdom (QMREC 2014:61). Written
informed consent was received from participants prior to inclusion in
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the study according to the Declaration of Helsinki. Neutrophils were
prepared following density separation by layering on Ficoll-Histopaque
1077−1. The cells were then centrifuged at 300g (30 min, 4 °C), and
contaminating red blood cells were lysed by hypotonic lyses as in ref 8.
Neutrophils 20 × 106 cells/mL (PBS+/+, pH = 7.45) were then
incubated with synthetic 13R-HDPA (5) (10 μM) for 45 min (37 °C).
Incubations were stopped with 2 volumes of ice-cold MeOH. NaBH4
was then added to reduce the hydroperoxides produced by the
neutrophil lipoxygenases (1.0 mg/mL; Sigma-Aldrich), and products
were isolated using C18 solid phase extraction as detailed below.
Lipid Mediator Proﬁling. MeOH (two volumes) was added to cell
incubations, plasma (mouse and human), and infectious exudates, and
samples were stored at −20 °C until extraction. Prior to extraction,
samples were then centrifuged (1200g, 4 °C, 10 min). Supernatants
were then collected and brought to less than 1.0 mL of MeOH content
using a gentle stream of nitrogen gas using a TurboVap LV system
(Biotage). The RvT1−4 and 13-HDPA products were extracted using
an ExtraHera (Biotage) automated extraction system as follows. Solid-
phase C18 cartridges were equilibrated with 3.0 mL of MeOH and 6.0
mL of H2O. Nine milliliters of aq HCl solution (pH = 3.5) was then
added to the samples, and the acidiﬁed solutions were rapidly loaded
onto the conditioned C18 columns that were washed with 4.0 mL of
H2O. Next, 5.0 mL of hexane was added, and the products were eluted
with 4.0 mL of methyl formate. Products were brought to dryness
using the automated evaporation system (TurboVap LV, Biotage) and
immediately suspended in MeOH−H20 (50:50 vol/vol) for LC-MS-
MS automated injections as previously reported.8
Extracted samples were analyzed by an LC-MS-MS system, Qtrap
5500 (AB Sciex) equipped with a Shimadzu SIL-20AC autoinjector
and LC-20AD binary pump (Shimadzu Corp.). A Poroshell C18
column (100 mm × 4.6 mm × 2.7 μm) was used with a gradient of
MeOH/H2O/AcOH of 55:45:0.01 (v/v/v) that was ramped to
85:15:0.01 (v/v/v) over 10 min and then to 98:2:0.01 (v/v/v) for the
next 8 min. This was subsequently maintained at 98:2:0.01 (v/v/v) for
2 min. The ﬂow rate was maintained at 0.4 mL per minute.
To monitor and quantify the levels of lipid mediators, a multiple
reaction monitoring (MRM) method was developed with signature
ion fragments (m/z) for each molecule monitoring the parent ion
(Q1) and a characteristic daughter ion (Q3). Identiﬁcation was
conducted using published criteria where a minimum of 6 diagnostic
ions were employed, see ref 18 for details. Detection limit was ∼0.1 pg.
For chiral-phase lipidomic analysis, a Chiralpak AD-RH column
(150 mm × 2.1 mm × 5 μm) was used with isocratic MeOH/H2O/
AcOH 95:5:0.01 (v/v/v) at 0.15 mL/min. To monitor isobaric
monohydroxy docosapentaenoic acid levels, a multiple reaction
monitoring (MRM) method was developed using signature ion
fragments 345 > 195 described.8
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